Omega-3 fatty acids in bipolar patients with a low omega-3 index and reduced heart rate variability: the "BIPO-3" trial.
Bipolar disorders
Heart rate variability, omega-3 index
Omega-3 fatty acids
Randomised controlled trial
Journal
International journal of bipolar disorders
ISSN: 2194-7511
Titre abrégé: Int J Bipolar Disord
Pays: Germany
ID NLM: 101622983
Informations de publication
Date de publication:
01 Apr 2022
01 Apr 2022
Historique:
received:
23
08
2021
accepted:
31
01
2022
entrez:
1
4
2022
pubmed:
2
4
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Research suggests that a low omega-3 index may contribute to the low heart rate variability and the increased risk of cardiovascular morbidity and mortality in bipolar disorders. However, so far, no intervention trial with EPA and DHA has been conducted in bipolar patients attempting to increase their heart rate variability. 119 patients with bipolar disorder according to DSM-IV were screened, with 55 euthymic bipolar patients-owing to inclusion criteria (e.g. low omega-3 index (< 6%), SDNN < 60 ms.)-being enrolled in a randomized, double-blind, 12-week parallel study design with omega-3 fatty acids (4 capsules of 530 mg EPA, 150 mg DHA) or corn oil as a placebo, in addition to usual treatment. Heart rate variability as well as the omega-3 index were measured at baseline and at the endpoint of the study. A total of 42 patients (omega-3: n = 23, corn oil: n = 19) successfully completed the study after 12 weeks. There was a significant increase in the omega-3 index (value at endpoint minus value at baseline) in the omega-3 group compared to the corn oil group (p < 0.0001). However, there was no significant difference in the change of the SDNN (value at endpoint minus value at baseline) between the treatment groups (p = 0.22). In addition, no correlation between changes in SDNN and change in the omega-3 index could be detected in the omega-3 group (correlation coefficient = 0.02, p = 0.94) or the corn oil group (correlation coefficient = - 0.11, p = 0.91). Similarly, no significant differences between corn oil and omega-3 group regarding the change of LF (p = 0.19), HF (p = 0.34) and LF/HF ratio (p = 0.84) could be demonstrated. In our randomized, controlled intervention trial in euthymic bipolar patients with a low omega-3 index and reduced heart rate variability no significant effect of omega-3 fatty acids on SDNN or frequency-domain measures HF, LF and LF/HF ratio could be detected. Possible reasons include, among others, the effect of psychotropic medication present in our trial and/or the genetics of bipolar disorder itself. Further research is needed to test these hypotheses. Trial registration ClinicalTrials.gov, NCT00891826. Registered 01 May 2009-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT00891826.
Sections du résumé
BACKGROUND
BACKGROUND
Research suggests that a low omega-3 index may contribute to the low heart rate variability and the increased risk of cardiovascular morbidity and mortality in bipolar disorders. However, so far, no intervention trial with EPA and DHA has been conducted in bipolar patients attempting to increase their heart rate variability.
METHODS
METHODS
119 patients with bipolar disorder according to DSM-IV were screened, with 55 euthymic bipolar patients-owing to inclusion criteria (e.g. low omega-3 index (< 6%), SDNN < 60 ms.)-being enrolled in a randomized, double-blind, 12-week parallel study design with omega-3 fatty acids (4 capsules of 530 mg EPA, 150 mg DHA) or corn oil as a placebo, in addition to usual treatment. Heart rate variability as well as the omega-3 index were measured at baseline and at the endpoint of the study.
RESULTS
RESULTS
A total of 42 patients (omega-3: n = 23, corn oil: n = 19) successfully completed the study after 12 weeks. There was a significant increase in the omega-3 index (value at endpoint minus value at baseline) in the omega-3 group compared to the corn oil group (p < 0.0001). However, there was no significant difference in the change of the SDNN (value at endpoint minus value at baseline) between the treatment groups (p = 0.22). In addition, no correlation between changes in SDNN and change in the omega-3 index could be detected in the omega-3 group (correlation coefficient = 0.02, p = 0.94) or the corn oil group (correlation coefficient = - 0.11, p = 0.91). Similarly, no significant differences between corn oil and omega-3 group regarding the change of LF (p = 0.19), HF (p = 0.34) and LF/HF ratio (p = 0.84) could be demonstrated.
CONCLUSIONS
CONCLUSIONS
In our randomized, controlled intervention trial in euthymic bipolar patients with a low omega-3 index and reduced heart rate variability no significant effect of omega-3 fatty acids on SDNN or frequency-domain measures HF, LF and LF/HF ratio could be detected. Possible reasons include, among others, the effect of psychotropic medication present in our trial and/or the genetics of bipolar disorder itself. Further research is needed to test these hypotheses. Trial registration ClinicalTrials.gov, NCT00891826. Registered 01 May 2009-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT00891826.
Identifiants
pubmed: 35362878
doi: 10.1186/s40345-022-00253-9
pii: 10.1186/s40345-022-00253-9
pmc: PMC8975918
doi:
Banques de données
ClinicalTrials.gov
['NCT00891826']
Types de publication
Journal Article
Langues
eng
Pagination
9Informations de copyright
© 2022. The Author(s).
Références
Am J Clin Nutr. 2013 May;97(5):926-35
pubmed: 23515005
J Cardiovasc Med (Hagerstown). 2007 Sep;8 Suppl 1:S46-9
pubmed: 17876200
Eur Heart J. 1996 Mar;17(3):354-81
pubmed: 8737210
Arch Gen Psychiatry. 2008 Dec;65(12):1358-67
pubmed: 19047522
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
J Affect Disord. 2015 Jul 15;180:142-7
pubmed: 25909752
Prog Neurobiol. 2015 Nov;134:36-54
pubmed: 26386135
Early Interv Psychiatry. 2016 Jun;10(3):203-11
pubmed: 26486098
Eur Psychiatry. 2015 Feb;30(2):228-32
pubmed: 25555342
J Clin Psychiatry. 2019 Jun 4;80(4):
pubmed: 31163106
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Pharmacol Ther. 2013 Oct;140(1):53-80
pubmed: 23735203
Prev Med. 2004 Jul;39(1):212-20
pubmed: 15208005
JAMA. 2009 Oct 21;302(15):1651-7
pubmed: 19843899
Prog Cardiovasc Dis. 2013 Sep-Oct;56(2):153-9
pubmed: 24215747
Epilepsy Res. 1998 Mar;30(1):77-83
pubmed: 9551847
Psychiatry Res. 2015 Dec 15;230(2):447-53
pubmed: 26477955
Prostaglandins Leukot Essent Fatty Acids. 2016 Apr;107:30-42
pubmed: 26858145
Bipolar Disord. 2018 Nov;20(7):658-665
pubmed: 29479787
Nutrients. 2020 Dec 02;12(12):
pubmed: 33276463
Am J Cardiol. 2006 Nov 15;98(10):1393-5
pubmed: 17134636
Prostaglandins Leukot Essent Fatty Acids. 2015 Jan;92:41-7
pubmed: 24935800
Lancet. 2012 Dec 15;380(9859):2163-96
pubmed: 23245607
Proc Nutr Soc. 2020 May 11;:1-7
pubmed: 32389149
Int J Mol Sci. 2020 Feb 18;21(4):
pubmed: 32085487
Aust N Z J Psychiatry. 2016 Jun;50(6):511-9
pubmed: 26698824
Med Hypotheses. 2017 Sep;107:29-34
pubmed: 28915957
Br J Soc Clin Psychol. 1967 Dec;6(4):278-96
pubmed: 6080235
Bipolar Disord. 2021 Nov;23(7):697-706
pubmed: 33340432
J Affect Disord. 2020 Apr 1;266:30-36
pubmed: 32056891
Arch Gen Psychiatry. 1999 Apr;56(4):380-1
pubmed: 10197836
Psychosom Med. 2010 Oct;72(8):748-54
pubmed: 20716712
Bipolar Disord. 2003 Apr;5(2):138-43
pubmed: 12680904
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):442-451
pubmed: 28764912
Cochrane Database Syst Rev. 2020 Feb 29;3:CD003177
pubmed: 32114706
Circulation. 2015 Sep 8;132(10):965-86
pubmed: 26260736
J Psychiatry Neurosci. 2016 Mar;41(2):89-104
pubmed: 26447819
Vascul Pharmacol. 2015 Aug;71:1-10
pubmed: 25869497
Biol Psychiatry. 2010 Jun 1;67(11):1067-74
pubmed: 20138254
J Am Heart Assoc. 2021 Apr 20;10(8):e017401
pubmed: 33840228
J Affect Disord. 2001 Dec;67(1-3):45-59
pubmed: 11869752
Psychol Med. 2015 Feb;45(3):623-36
pubmed: 25075912
Transl Psychiatry. 2016 May 10;6:e803
pubmed: 27163204
Front Physiol. 2012 Apr 17;3:88
pubmed: 22529815
Arch Gen Psychiatry. 2011 Mar;68(3):241-51
pubmed: 21383262
Curr Opin Neurobiol. 2016 Feb;36:1-6
pubmed: 26210959
Internist (Berl). 2019 Dec;60(12):1319-1327
pubmed: 31591673
Bipolar Disord. 2015 Aug;17(5):543-8
pubmed: 25846854
J Clin Psychiatry. 2016 Oct;77(10):e1301-e1308
pubmed: 27631140
JAMA. 2020 Dec 8;324(22):2268-2280
pubmed: 33190147
Pharmacopsychiatry. 2016 Sep;49(5):191-198
pubmed: 27023265
N Engl J Med. 2019 Jan 3;380(1):11-22
pubmed: 30415628
Bipolar Disord. 2016 May;18(3):300-6
pubmed: 27087497
J Cardiovasc Med (Hagerstown). 2007 Sep;8 Suppl 1:S19-22
pubmed: 17876192
J Clin Psychiatry. 2016 Feb;77(2):e138-43
pubmed: 26930527
J Clin Psychiatry. 2015 Feb;76(2):163-9
pubmed: 25742203
Am J Cardiol. 1995 Nov 1;76(12):906-12
pubmed: 7484830
Nat Commun. 2021 Apr 22;12(1):2329
pubmed: 33888689
Acta Psychiatr Scand. 2014 Nov;130(5):342-53
pubmed: 24850482
Circulation. 1995 Apr 1;91(7):1936-43
pubmed: 7895350
Psychiatry Res. 1997 Dec 5;73(3):159-71
pubmed: 9481807
Neurosci Biobehav Rev. 2017 Feb;73:68-80
pubmed: 27986468
Arch Intern Med. 2005 Jul 11;165(13):1486-91
pubmed: 16009863
Transl Psychiatry. 2019 Aug 5;9(1):190
pubmed: 31383846
Am J Cardiol. 2010 Apr 15;105(8):1181-5
pubmed: 20381674
Psychother Psychosom. 2019;88(5):263-273
pubmed: 31480057